Gouws Capital LLC Lowers Stock Position in Amgen Inc. $AMGN

Key Points

• Gouws Capital LLC reduced its Amgen stake by 41.9% in Q4, selling 5,610 shares and now holding 7,795 shares worth $2,551,000 (AMGN is 1.3% of the firm's holdings and its 21st largest position).
• Amgen beat Q1 estimates with $5.15 EPS and $8.62B revenue, reported ~4% product sales growth, set FY‑2026 EPS guidance of $21.70–$23.10, and declared a $2.52 quarterly dividend (annualized yield ~3.1%).
• Analyst sentiment is mixed—some firms raised price targets (e.g., Daiwa to $410, Goldman to $425) but MarketBeat's consensus rating is a Hold with an average target of $357.54, while FDA scrutiny over Tavneos poses regulatory downside risk.

Gouws Capital LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 41.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,795 shares of the medical research company's stock after selling 5,610 shares during the period. Amgen comprises 1.3% of Gouws Capital LLC's holdings, making the stock its 21st biggest position. Gouws Capital LLC's holdings in Amgen were worth $2,551,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. West Family Investments Inc. lifted its position in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after purchasing an additional 30 shares during the period. Viawealth LLC lifted its position in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd lifted its position in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after acquiring an additional 30 shares during the last quarter. Smith Salley Wealth Management lifted its position in Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock valued at $3,530,000 after acquiring an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC lifted its position in Amgen by 4.0% during the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company's stock valued at $257,000 after acquiring an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

AMGN has been the subject of a number of analyst reports. Daiwa Securities Group increased their target price on shares of Amgen from $370.00 to $410.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. TD Cowen reissued a "buy" rating on shares of Amgen in a research report on Wednesday, February 4th. Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a "hold" rating and a $350.00 target price for the company. Barclays initiated coverage on shares of Amgen in a research report on Friday, February 20th. They set an "equal weight" rating and a $350.00 target price for the company. Finally, Royal Bank Of Canada increased their target price on shares of Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $357.54.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Stock Performance

NASDAQ AMGN opened at $329.82 on Monday. The company has a fifty day simple moving average of $358.07 and a two-hundred day simple moving average of $341.12. The stock has a market cap of $178.00 billion, a P/E ratio of 22.95, a P/E/G ratio of 3.24 and a beta of 0.44. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 0.90 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts' expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts forecast that Amgen Inc. will post 22.28 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen's dividend payout ratio (DPR) is currently 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.